Add To Watchlist
Share URL
Roivant Sciences Ltd.
ROIV: NasdaqGSLowest reading is at 2 out of 100. All scores are out of 100.
In Short
About The Company
CEO
Mr. Matthew Gline
Market Cap
24.22 Billion USD
Sector
Healthcare
Website
https://roivant.comLast Update
15/10/2026, 01:00:51
Description
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies.
Read More
Strongest readings
- ✔Altman-Z score of 20.00 sits above the distress range
- ✔Debt is low at 0.02 times equity
Weakest readings
- ✘Income is not covering expenditure and investment (free cashflow -1.20 per share)
- ✘Earnings are negative at -0.43 per share
- ✘Earnings and cashflow growth is weak (growth score 2 out of 100)
- ✘Priced well above the cashflow it produces (value score 14 out of 100)
- ✘The current price sits above estimated fair value (margin of safety -79.90%)
Key Figures
| Status | Metric | Value | Reading | Market avg |
|---|---|---|---|---|
Price / earnings (TTM) | N/A | 19.60x | ||
| ✘ | Margin of safety (DCF) | -79.90% | 17.95% | |
| ✘ | Revenue growth (5y average) | -11.19% | 10.97% | |
| ✘ | Dividend yield (TTM) | 0.00% | 1.85% | |
| ✘ | Share count, per year | 0.89% | 0.00% | |
| ✘ | Return on capital employed | -23.68% | 10.00% |
The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.
Valuation
14 / 100Priced above the market on most measures.
| Status | Metric | Value | Reading | Market avg |
|---|---|---|---|---|
Price / earnings | N/A | 19.60x | ||
| ✘ | Free cashflow yield | -3.53% | 4.70% | |
| Price / earnings growth | N/A | 1.50x | ||
| Price / book | 4.98x | — | ||
| ✘ | Margin of safety | -79.90% | 17.95% |
The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.
- ✘Estimated intrinsic value of 6.81 USD is below the current price of 33.53 USD
Desired Margin Of Safety
0%
▼
Tip: Set your desired Margin Of Safety
Free Cash Flow Type
Annual Cashflow Growth
0%
Discount Rate
0%
Estimated Fair Value: N/A✘
Current Price: 33.9 USD
Negative Cashflows: Cashflow can become negative due to operating losses, investing activities or financing activites. Negative cashflow makes it dificult to use a discounted free cashflow model to assess intrinsic value.
How Does This Work?
Show Advanced Options
This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated fair value for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel for the impact this has on longterm investment returns and find a margin of safety you are comfortable with.
Growth
2 / 100Growing more slowly than the market on most measures.
| Status | Metric | Value | Reading | Market avg |
|---|---|---|---|---|
| ✘ | Revenue growth | -11.19% | 10.97% | |
| Earnings growth | N/A | 14.48% | ||
| Cashflow growth | N/A | 12.35% |
The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.
- ✘Revenue growth has slowed this year (-80.61% against a five year average of -11.19%)
Health
51 / 100Balance sheet covers its obligations.
Measured on Leverage and capital, Funding and liquidity, Earnings quality.
| Status | Metric | Value | Reading | Threshold |
|---|---|---|---|---|
| ✔ | Altman-Z score | 20.00 | 3.00 | |
| ✘ | Piotroski score | 1.00 | 5.00 | |
| ✔ | Debt / equity | 0.02x | 0.80x | |
| ✔ | Current ratio | 18.37x | 1.00x | |
| ✘ | Interest coverage | -23.72x | 2.50x | |
| ✘ | Free cashflow / debt | 0.00x | 0.15x | |
| ✔ | Debt / capital | 0.02x | 1.00x |
The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.
- ✘Income is not covering expenditure and investment (free cashflow -1.20 per share)
Management
52 / 100Returns on capital are at or above the market.
| Status | Metric | Value | Reading | Market avg |
|---|---|---|---|---|
| ✘ | Return on equity | -6.62% | 15.00% | |
| ✘ | Return on capital employed | -23.68% | 10.00% | |
| Return on assets | -5.25% | — | ||
| Free cashflow return on capital | -13.98% | — | ||
| ✔ | Return on capital, 5y change | 28.36% | 0.00% | |
| ✘ | Share count, per year | 0.89% | 0.00% | |
| ✘ | Share count, recent | 4.10% | 0.00% | |
| ✔ | Realized buyback return | 87.89% | 0.00% | |
| ✔ | Goodwill erosion / equity | 0.00% | 2.00% | |
| Price volatility, 5 year | 57.54% | — |
The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.
- ✔New shares were issued while the value score was 14 out of 100
Analysts
not enough data| Status | Metric | Value | Reading | Neutral |
|---|---|---|---|---|
| Analyst opinion score | N/A | 50 |
The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.
Financial History
Annual figures across the full reporting history we hold.
Market Peers
ROIV
SEC Filings
Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.
See 35+ Years Annual ReportsOther Information
Company Name
Roivant Sciences Ltd.
Currency
USD
Beta
1.122
Vol Avg
7050738
Ceo
Mr. Matthew Gline
Cik
0001635088
Cusip
Exchange
NasdaqGS
Full Time Employees
721
Industry
Biotechnology
Sector
Healthcare
Ipo Date
Address
50 Broadway
City
London
State
Country
United Kingdom
Zip
SW1H 0DB
Phone
44 20 7400 3347
Analysis Last Updated
15/10/2026, 01:00:51
Financial data compiled from SEC EDGAR filings and Yahoo Finance.